GlassScriptPhysician profile
Reginald Vinson Hall
NPI 1902885494
$15,527.89
in general payments reported to CMS, 2019-2025
52 companies · $1,238 in 2025
The $1,238 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,957 · 2020: $1,807 · 2021: $2,377 · 2022: $2,860 · 2023: $2,060 · 2024: $1,229 · 2025: $1,238.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,527.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,526.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $5,100.16 | 2019-2025 | Ultomiris |
| Abbvie INC. | $1,310.36 | 2021-2025 | |
| Ucb, INC. | $950.72 | 2019-2025 | Briviact, Nayzilam, Zilbrysq |
| Novartis Pharmaceuticals Corporation | $728.37 | 2021-2025 | |
| Upsher-Smith Laboratories LLC | $696.63 | 2020-2023 | |
| Teva Pharmaceuticals USA, INC. | $627.19 | 2020-2024 | Austedo Xr, Ajovy, Austedo |
| Mallinckrodt Hospital Products INC. | $537.38 | 2021-2025 | Acthar |
| Biogen, INC. | $536.49 | 2019-2023 | Vumerity, Plegridy, Tysabri |
| Pfizer INC. | $385.84 | 2019-2025 | |
| Neurocrine Biosciences, INC. | $305.87 | 2022-2025 | Ingrezza, Ongentys |
| Kyowa Kirin, INC. | $288.60 | 2020-2023 | Nourianz |
| Biohaven Pharmaceutical Holding Company LTD. | $264.94 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $264.63 | 2020-2021 | |
| Avanir Pharmaceuticals, INC. | $234.16 | 2019-2022 | |
| Amgen INC. | $230.51 | 2020-2023 | Aimovig |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $193.19 | 2020-2022 | |
| Ani Pharmaceuticals, INC. | $172.38 | 2023-2025 | Purified Cortrophin Gel |
| Lilly USA, LLC | $164.92 | 2019-2024 | Emgality, Amyvid |
| Janssen Pharmaceuticals, INC | $151.75 | 2019-2022 | |
| Lundbeck LLC | $142.50 | 2022-2023 | Vyepti |
| Astrazeneca Pharmaceuticals LP | $138.63 | 2021 | |
| Eisai INC. | $131.90 | 2021-2023 | |
| Mdd US Operations, LLC | $124.99 | 2022-2025 | Gocovri, Qelbree, Gocovri |
| Avion Pharmaceuticals | $117.35 | 2022-2023 | Dhivy |
| Sunovion Pharmaceuticals INC. | $108.71 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $104.14 | 2021-2022 | |
| Genentech USA, INC. | $103.52 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $99.66 | 2020-2022 | |
| Grifols USA, LLC | $97.08 | 2022-2025 | Gamunex-C |
| Celgene Corporation | $94.40 | 2021-2023 | Zeposia |
| Ge Healthcare | $93.50 | 2019-2023 | |
| Acadia Pharmaceuticals INC | $91.02 | 2019-2022 | |
| Sk Life Science, INC. | $89.78 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $84.26 | 2023-2025 | Rexulti |
| Janssen Biotech, INC. | $77.85 | 2025 | |
| Argenx US, INC. | $75.74 | 2022-2023 | Vyvgart |
| Impel Pharmaceuticals INC. | $71.37 | 2022-2023 | Trudhesa |
| Supernus Pharmaceuticals, INC. | $60.69 | 2020-2022 | |
| Neurelis, INC. | $58.37 | 2022-2024 | Valtoco |
| Amneal Pharmaceuticals LLC | $54.21 | 2020-2022 | |
| W. L. Gore & Associates, INC. | $47.91 | 2021 | |
| Azurity Pharmaceuticals, INC. | $45.12 | 2023 | Horizant |
| Scilex Pharmaceuticals INC. | $43.75 | 2023-2024 | Ztlido |
| Corium, LLC | $38.00 | 2023 | Adlarity |
| Aucta Pharmaceuticals, INC. | $37.11 | 2024-2025 | Motpoly Xr |
| Acorda Therapeutics, INC | $34.85 | 2022 | |
| Banner Life Sciences, LLC | $24.41 | 2022 | |
| Csl Behring | $24.13 | 2024 | Hizentra |
| Vanda Pharmaceuticals INC. | $21.21 | 2024 | Ponvory |
| Viiv Healthcare Company | $20.86 | 2025 | Apretude |
| Emd Serono, INC. | $16.54 | 2022 | |
| Impel Pharmaceuticals LLC | $10.24 | 2024 | Trudhesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reginald Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.